Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

In Vivo Activity of Amodiaquine against Ebola Virus Infection.

DeWald LE, Johnson JC, Gerhardt DM, Torzewski LM, Postnikova E, Honko AN, Janosko K, Huzella L, Dowling WE, Eakin AE, Osborn BL, Gahagen J, Tang L, Green CE, Mirsalis JC, Holbrook MR, Jahrling PB, Dyall J, Hensley LE.

Sci Rep. 2019 Dec 27;9(1):20199. doi: 10.1038/s41598-019-56481-0.

2.

A Pharmacoepidemiologic Study of the Safety and Effectiveness of Clindamycin in Infants.

Greenberg RG, Wu H, Maharaj A, Cohen-Wolkowiez M, Tomashek KM, Osborn BL, Clark RH, Walter EB.

Pediatr Infect Dis J. 2020 Mar;39(3):204-210. doi: 10.1097/INF.0000000000002524.

PMID:
31725114
3.

Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model.

Connolly KL, Eakin AE, Gomez C, Osborn BL, Unemo M, Jerse AE.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01644-18. doi: 10.1128/AAC.01644-18. Print 2019 Mar.

4.

A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.

Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM.

Antivir Ther. 2006;11(1):35-45.

PMID:
16518958
5.

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.

Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM.

J Hepatol. 2006 Apr;44(4):671-8. Epub 2006 Jan 30.

PMID:
16487617
6.

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.

Subramanian GM, Cronin PW, Poley G, Weinstein A, Stoughton SM, Zhong J, Ou Y, Zmuda JF, Osborn BL, Freimuth WW.

Clin Infect Dis. 2005 Jul 1;41(1):12-20. Epub 2005 May 24.

PMID:
15937757
7.

Development of a long-acting insulin analog using albumin fusion technology.

Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral OK, Chen C, Zhang G, Kaithamana S, Singh M, Schulingkamp R, Crossan D, Bock J, Kaufman TE, Reavey P, Carey-Barber M, Krishnan SR, Garcia A, Murphy K, Siskind JK, McLean MA, Cheng S, Ruben S, Birse CE, Blondel O.

Diabetes. 2005 Jan;54(1):251-8.

8.

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.

Melder RJ, Osborn BL, Riccobene T, Kanakaraj P, Wei P, Chen G, Stolow D, Halpern WG, Migone TS, Wang Q, Grzegorzewski KJ, Gallant G.

Cancer Immunol Immunother. 2005 Jun;54(6):535-47. Epub 2004 Dec 8.

PMID:
15592670
9.

New and modified interferon alfas: preclinical and clinical data.

Masci P, Bukowski RM, Patten PA, Osborn BL, Borden EC.

Curr Oncol Rep. 2003 Mar;5(2):108-13. Review.

PMID:
12583827
10.

Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.

Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ.

Eur J Pharmacol. 2002 Dec 5;456(1-3):149-58.

PMID:
12450581
11.

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.

Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C.

J Pharmacol Exp Ther. 2002 Nov;303(2):540-8.

PMID:
12388634
12.
13.

Isotopic differences in human growth hormone preparations.

Abramson FP, Osborn BL, Teffera Y.

Anal Chem. 1996 Jun 1;68(11):1971-2.

PMID:
8686917
14.
15.

Quantitation of human plasma levels of the anticancer agent carboxyamidotriazole by high-performance liquid chromatography.

Holmes KA, Chaffins S, Osborn BL, Liotta LA, Kohn EC.

J Chromatogr. 1993 Apr 2;613(2):317-25.

PMID:
8491819
16.

Chloroquinoxaline sulfonamide: a sulfanilamide antitumor agent entering clinical trials.

Fisherman JS, Osborn BL, Chun HG, Plowman J, Smith AC, Christian MC, Zaharko DS, Shoemaker RH.

Invest New Drugs. 1993 Feb;11(1):1-9. Review.

PMID:
8349430

Supplemental Content

Loading ...
Support Center